Radiotherapy with ADT outperforms radical prostatectomy strategies in reducing the risk for distant metastasis but results in ...

The ArteraAI Prostate Test is intended to assist clinicians and patients with risk-based decisions in localized prostate cancer.

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit ...

A new study links statin use to better overall survival in men with advanced prostate cancer who received apalutamide, but ...

Men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle, despite no reduction in prostate cancer-specific mortality, according to a large observational study. A ...

Healthy lifestyle and dietary choices are associated with a reduction in the risk of all-cause death among patients with non-metastatic prostate cancer, researchers found.

In the US, prostate cancer is the second leading cause of cancer death in men – but experts can’t agree about testing ...

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

Beyond the measurable reduction in prostate size, participants reported less pain and discomfort and improved urine flow, with initial changes typically noted within one week of starting the protocol.

Testing the molecular profile of tumours identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live ...

As the name implies, the new TULSA-AI ® Volume Reduction module streamlines TULSA procedures intended to decrease the volume of obstructive prostate tissue in men with LUTS due to BPH.